Provided are an odorant receptor marker of microglia and a use thereof, and according to the odorant receptor marker of microglia and a use thereof according to one aspect, microglia may be detected by measuring an activity or expression level of a protein of an odorant receptor (OR) Olfr110 or Olfr111, and OR ligands of microglia may be selected using them, and an inhibitor or activator against the interaction between the OR and 2-pentylfuran is effectively used in treatment of a neuroinflammatory disease or meningitis.

Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and/or BLV infections.

The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.

Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and nonalcoholic steatohepatitis.

Provided is a method for treating gastric cancer by blocking a CCL28 chemotactic pathway. Specifically, provided is a use of a CCL28 gene or CCL28 protein for preparing a reagent or a kit for testing gastric cancer. The gastric cancer has an abnormal up-regulated expression of both a Wnt/β-catenin signaling pathway and molecules related to CCL28 chemokine. Also provided are a testing kit, a use of a pharmaceutical composition, and a method for inhibiting the growth of cancer cells in vivo and in vitro.

The invention relates to a new method of delivering an analyte to a transmembrane pore in a membrane. The method involves the use of microparticles.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

A device for collecting, preserving and storing a sample of biological fluid comprising a porous medium for collecting and maintaining the membrane integrity of the eukaryotic cells contained in the sample, and their constituents is disclosed, the medium comprising at least 80% by weight of artificial components, advantageously at least 85%, preferably at least 90% of a total weight of the medium; and having a mean flow pore size (MFP) of at least 3 μm.

An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.

The present invention relates to a lectin-macromolecular carrier coupling complex for separating glycosylated exosomes from a clinical sample, which comprises a macromolecular carrier and lectins coupled to the outer side of the macromolecular carrier. The complex may simply, conveniently, rapidly, and accurately separate glycosylated exosomes from a clinical sample with a high separation efficiency and a good repeatability; and the separated exosomes are intact in morphology without rupturing or cracking, may be directly used for liquid detection of glycosylated exosomes, or directly used for immunology-related detection, or directly used for gene detection or analysis after extracting related nucleic acids from the exosomes.